Optogenetics in cancer drug discovery.

Autor: Kiełbus M; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland., Czapiński J; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland.; b Postgraduate School of Molecular Medicine , Medical University of Warsaw , Warsaw , Poland., Odrzywolski A; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland., Stasiak G; c Department of Experimental Haematooncology , Medical University of Lublin , Lublin , Poland., Szymańska K; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland., Kałafut J; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland., Kos M; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland., Giannopoulos K; c Department of Experimental Haematooncology , Medical University of Lublin , Lublin , Poland.; d Department of Hematology , St. John's Cancer Center , Lublin , Poland., Stepulak A; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland., Rivero-Müller A; a Department of Biochemistry and Molecular Biology , Medical University of Lublin , Lublin , Poland.; e Cell Biology, Faculty of Science and Engineering , Åbo Akademi University , Turku , Finland.
Jazyk: angličtina
Zdroj: Expert opinion on drug discovery [Expert Opin Drug Discov] 2018 May; Vol. 13 (5), pp. 459-472. Date of Electronic Publication: 2018 Feb 15.
DOI: 10.1080/17460441.2018.1437138
Abstrakt: Introduction: The discovery and domestication of biomolecules that respond to light has taken a light of its own, providing new molecular tools with incredible spatio-temporal resolution to manipulate cellular behavior. Areas covered: The authors herein analyze the current optogenetic tools in light of their current, and potential, uses in cancer drug discovery, biosafety and cancer biology. Expert opinion: The pipeline from drug discovery to the clinic is plagued with drawbacks, where most drugs fail in either efficacy or safety. These issues require the redesign of the pipeline and the development of more controllable/personalized therapies. Light is, aside from inexpensive, almost harmless if used appropriately, can be directed to single cells or organs with controllable penetration, and comes in a variety of wavelengths. Light-responsive systems can activate, inhibit or compensate cell signaling pathways or specific cellular events, allowing the specific control of the genome and epigenome, and modulate cell fate and transformation. These synthetic molecular tools have the potential to revolutionize drug discovery and cancer research.
Databáze: MEDLINE